Related Experiment Video
Updated: Jun 17, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sorafenib.
1Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79102, Freiburg, Germany. jens.hasskarl@uniklinik-freiburg.de
Summary
Sorafenib is an oral kinase inhibitor targeting cancer pathways like raf-ras and VEGF. It is approved for advanced kidney and liver cancer, with ongoing trials for other tumor types.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sorafenib is an oral kinase inhibitor targeting multiple tyrosine kinases.
- Key targets include receptor tyrosine kinase pathways deregulated in cancer, such as raf-ras, VEGF, and FLT3.
Purpose of the Study:
- To summarize the role of sorafenib in cancer treatment.
- To highlight its mechanism of action and clinical applications.
Main Methods:
- Review of in vitro and in vivo studies.
- Analysis of clinical trial data for various tumor entities.
Main Results:
- Sorafenib targets multiple receptor tyrosine kinases involved in cancer.
- FDA approval for advanced renal cell and hepatocellular cancer.
- Demonstrated clinical activity in thyroid cancer.
Conclusions:
- Sorafenib is a validated therapeutic agent for specific advanced cancers.
- Further clinical trials are investigating its efficacy in broader oncological settings.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...